Characterization of the thymus in Lrp4 myasthenia gravis

• Verfasst von: Koneczny, Inga [VerfasserIn]
• Verfasst von: Marx, Alexander [VerfasserIn]
• Titel: Characterization of the thymus in Lrp4 myasthenia gravis
• Titelzusatz: four cases
• Verf.angabe: Inga Koneczny, Dorit Rennspiess, Florit Marcuse, Nathalie Dankerlui, Myurgia Abdul Hamid, Marina Mané-Damas, Jos Maessen, Paul Van Schil, Abhishek Saxena, Paraskevi Zisimopoulou, Konstantinos Lazaridis, Mark Woodhall, Katerina Karagiorgou, John Tzartos, Socrates Tzartos, Marc H. De Baets, Peter C. Molenaar, Alexander Marx, Axel zur Hausen, Mario Losen, Pilar Martinez-Martinez
• Jahr: 2019
• Jahr des Originals: 2018
• Umfang: 6 S.
• Fussnoten: Available online 08 November 2018 ; Gesehen am 15.01.2020
• Titel Quelle: Enthalten in: Autoimmunity reviews
• Ort Quelle: Amsterdam [u.a.] : Elsevier Science, 2002
• Jahr Quelle: 2019
• Band/Heft Quelle: 18(2019), 1, Seite 50-55
• ISSN Quelle: 1873-0183
• DOI: doi:10.1016/j.autrev.2018.07.011
• Datenträger: Online-Ressource
• Sprache: eng
• K10plus-PPN: 168746751X

Abstract

Myasthenia gravis (MG) is an autoimmune disease of the neuromuscular junction. Most patients have pathogenic autoantibodies against the acetylcholine receptor (AChR). In the last years a novel subpopulation of MG patients has been described that harbors antibodies against low-density lipoprotein receptor-related protein 4 (Lrp4), another postsynaptic neuromuscular antigen. In early-onset AChR MG (EOMG), the thymus plays an important role in immunopathogenesis, and early thymectomy is beneficial. It is still unknown if the thymus plays any role in Lrp4-MG. In this pilot study, we compared thymus samples from four patients with Lrp4-MG (one pre-treated with immunosuppressive drugs), four non-MG controls and five EOMG patients (not pretreated with immunosuppressive drugs).